Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
Case Rep Emerg Med ; 2018: 3452691, 2018.
Article in English | MEDLINE | ID: mdl-29682363

ABSTRACT

Ayahuasca is a hallucinogenic tea that is most commonly comprised of the vine Banisteriopsis caapi alone or in combination with other plants such as Psychotria viridis. This concoction results in an orally active form of dimethyltryptamine (DMT), a hallucinogenic amine. Despite use in South America as a medicinal agent and component in religious ceremonies, interest in its recreational use and spiritual effects has led to increased use in the United States. We describe a unique case following ingestion of ayahuasca tea in a patient with history of schizophrenia resulting in personal injury and property damage. A review of ayahuasca toxicity and evaluation of serious adverse effects is also presented.

3.
J Med Toxicol ; 11(2): 218-22, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25896948

ABSTRACT

INTRODUCTION: Acetaminophen-cysteine adducts (APAP-CYS) are a serum biomarker of acetaminophen exposure, formed when the oxidative metabolite of acetaminophen binds to cysteine residues of hepatic proteins. APAP-CYS adducts become elevated in cases of acute liver failure following acetaminophen overdose and have been proposed as a diagnostic tool to identify acetaminophen-induced acute liver failure when standard testing is inconclusive. CASE REPORT: A 26-year-old female with history of unexplained, severe hepatitis presented with a second episode of severe hepatitis including coagulopathy and transaminase levels >10,000 U/L. The patient reported ingesting "only a couple" of acetaminophen tablets several days prior to her presentation. An acetaminophen concentration of 14 mcg/mL at presentation aroused suspicion that acetaminophen might have caused the patient's liver failure, despite her adamant denial of overdose. APAP-CYS adduct levels measured from serum obtained 4 days after her presentation and in two consecutive serum samples are reported alongside previously reported APAP-CYS levels. DISCUSSION: The patient's APAP-CYS adduct levels were consistent with those seen in acute liver injury due to acetaminophen toxicity, even up to 1 week following presentation, and allowed for confirmation of acetaminophen toxicity as the cause of the her hepatitis. Overall, this case demonstrates the real-time application of APAP-CYS adducts as a biomarker to diagnose acetaminophen toxicity in patients with indeterminate acute liver failure.


Subject(s)
Acetaminophen/analogs & derivatives , Acetaminophen/analysis , Acetaminophen/poisoning , Analgesics, Non-Narcotic/analysis , Analgesics, Non-Narcotic/poisoning , Cysteine/analogs & derivatives , Liver Failure, Acute/diagnosis , Adult , Biomarkers/analysis , Centrifugation , Cysteine/analysis , Dialysis , Drug Overdose/diagnosis , Female , Humans , Liver Failure, Acute/chemically induced , Liver Function Tests
4.
J Med Toxicol ; 10(2): 205-9, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24798647

ABSTRACT

INTRODUCTION: Physostigmine was once a widely used antidote for the treatment of antimuscarinic toxicity. However, reports describing the association of physostigmine with asystole and seizures in severe tricyclic antidepressant poisoning resulted in a decrease in use. Recent literature has demonstrated that physostigmine is a safe and effective antidote for the treatment of antimuscarinic toxicity. There are only two previously published articles regarding the use of physostigmine administered as a continuous intravenous infusion for persistent antimuscarinic toxicity. We present a case of physostigmine continuous infusion for the treatment of antimuscarinic symptoms in a polydrug overdose due to the ingestion of diphenhydramine along with bupropion, citalopram, acetaminophen, and naproxen. CASE PRESENTATION: A 13-year-old female presented with hyperthermia, myoclonus and rigidity, hallucinations, severe agitation, and antimuscarinic toxicity including inability to sweat after a polydrug overdose. Several doses of lorazepam were administered followed by physostigmine which produced resolution of hallucinations and attenuation of the antimuscarinic symptoms including perspiration, temperature improvement, and decreased agitation. After periods of improvement and recurrence of antimuscarinic effects, a continuous infusion of physostigmine was administered at 2 mg/h and continued for almost 8 h to maintain attenuation of symptoms. GABAergic agents including lorazepam and phenobarbital were used later in the hospital course for presumed symptoms of serotonergic and adrenergic toxicity after resolution of antimuscarinic effects. The patient did not experience any adverse effects of physostigmine administration. DISCUSSION: Physostigmine administered as a continuous infusion may be a reasonable treatment option for severe and recurrent symptoms related to antimuscarinic toxicity.


Subject(s)
Antidotes/administration & dosage , Cholinesterase Inhibitors/administration & dosage , Drug Overdose/drug therapy , Muscarinic Antagonists/poisoning , Physostigmine/administration & dosage , Suicide, Attempted , Adolescent , Antidotes/adverse effects , Antidotes/therapeutic use , Cholinesterase Inhibitors/adverse effects , Cholinesterase Inhibitors/therapeutic use , Combined Modality Therapy/adverse effects , Drug Overdose/physiopathology , Drug Therapy, Combination/adverse effects , Female , Humans , Infusions, Intravenous , Muscarinic Antagonists/chemistry , Physostigmine/adverse effects , Physostigmine/therapeutic use , Polypharmacy , Recurrence , Severity of Illness Index , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...